Upadacitinib Restores Hair in 55% of Severe Alopecia Patients in Phase 3 Trials
Updated
Updated · The Medical Republic · Aug 20
Upadacitinib Restores Hair in 55% of Severe Alopecia Patients in Phase 3 Trials
3 articles · Updated · The Medical Republic · Aug 20
Summary
Two global phase 3 trials found 44.6%-55.0% of adolescents and adults on daily upadacitinib reached SALT20 by 24 weeks, versus 1.5%-3.4% on placebo.
The stronger 30 mg dose showed earlier and deeper responses, with 11.8% reaching SALT20 by week 8 and 20.3%-22.5% achieving complete scalp regrowth by week 24.
Upadacitinib also improved eyebrow and eyelash regrowth and was linked to lower anxiety and depression scores, extending benefits beyond scalp hair restoration.
Pooled safety data from 1,399 patients showed more adverse events with 30 mg than 15 mg or placebo, but no deaths; 23 serious adverse events were recorded across both studies.
Researchers said the 24-week benefit-risk profile was positive and noted a third study is underway to test long-term efficacy, safety and dose adjustments through week 52.